Chemours outlines 2025 adjusted EBITDA guidance at $825M-$950M amid Opteon growth and cost reductions

Disclosure: This website may contain affiliate links, which means I may earn a commission if you click on the link and make a purchase. I only recommend products or services that I personally use and believe will add value to my readers. Your support is appreciated!